These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31283034)

  • 1. Prognostic role of pathologic response and cytoreductive status at interval debulking surgery after neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
    Liang MI; Prendergast EN; Staples JN; Holschneider CH; Cohen JG; Cass I
    J Surg Oncol; 2019 Sep; 120(4):779-785. PubMed ID: 31283034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.
    Petrillo M; Zannoni GF; Tortorella L; Pedone Anchora L; Salutari V; Ercoli A; Margariti PA; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2014 Dec; 211(6):632.e1-8. PubMed ID: 24954656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
    Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
    J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy.
    Fagotti A; Gueli Alletti S; Corrado G; Cola E; Vizza E; Vieira M; Andrade CE; Tsunoda A; Favero G; Zapardiel I; Pasciuto T; Scambia G
    Int J Gynecol Cancer; 2019 Jan; 29(1):5-9. PubMed ID: 30640676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
    Zhao D; Wu LY; Wang XB; Li XG
    Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.
    Van de Putte G; Oben J; Prenen L; Schobbens JC; Vlasselaer J; Van Holsbeke C; Debrock G; Van Eycken P; de Jonge E
    Int J Gynecol Cancer; 2015 Jul; 25(6):993-9. PubMed ID: 25914962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with
    Kim SR; Parbhakar A; Li X; Bernardini MQ; Hogen L; May T
    Int J Gynecol Cancer; 2024 Jun; 34(6):879-885. PubMed ID: 38548312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
    Ren Y; Shi T; Jiang R; Yin S; Wang P; Zang R
    Int J Gynecol Cancer; 2015 Oct; 25(8):1398-404. PubMed ID: 26222486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
    AlSomairi A; Himayda S; Altelmesani A; Lee YJ; Lee JY
    Gynecol Oncol; 2024 Feb; 181():155-161. PubMed ID: 38176127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy.
    Corrado G; Mancini E; Cutillo G; Baiocco E; Vici P; Sergi D; Patrizi L; Saltari M; Baffa A; Vizza E
    Int J Gynecol Cancer; 2015 Sep; 25(7):1253-7. PubMed ID: 26111273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
    Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
    [No Abstract]   [Full Text] [Related]  

  • 15. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
    Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
    Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
    Piedimonte S; Murray C; Atenafu EG; Rouzbahman M; Lheureux S; May T
    Gynecol Oncol; 2024 Aug; 187():92-97. PubMed ID: 38735145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
    Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
    Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
    da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
    Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
    Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.